Business Context and Reporting Period
Prestige Brands Holdings, Inc. (now Prestige Consumer Healthcare Inc.) filed this Form 8-K on March 30, 2012, reporting the completion of an asset acquisition. The company operates in the over-the-counter (OTC) pharmaceutical sector.
Key Financial Metrics
- Acquisition Cost: $45 million in cash for the Debrox and Gly-Oxide brands, subject to a post-closing inventory adjustment.
- Funding Sources: The transaction was funded using cash from the company's $660 million New Term Loan Facility and $250 million in Senior Notes.
- Revenue/Profit/Cash Flow: The filing text does not provide specific revenue, profit, cash flow, margin, or liquidity figures for the reporting period.
Material Changes
The primary material change is the completion of the acquisition of the Debrox and Gly-Oxide OTC pharmaceutical brands, including related contracts, trademarks, and inventory, from GlaxoSmithKline plc (GSK). This transaction finalizes the company's acquisition of a total of 17 OTC pharmaceutical brands from GSK, following the completion of 15 other brands on January 31, 2012.
Outlook, Risks, and Unusual Items
- Future Filings: Financial statements of the acquired business and pro forma financial information are not included in this report; they will be filed via amendment within 71 calendar days.
- Regulatory Disclosure: A press release regarding the acquisition completion was issued on April 2, 2012, under Regulation FD.
- Risks: The filing does not explicitly detail new risks, though the transaction involves a post-closing inventory adjustment which could alter the final purchase price.
Investor Verification Checklist
- Verify the final purchase price after the post-closing inventory adjustment is determined.
- Review the upcoming amendment to this 8-K for the financial statements of the acquired Debrox and Gly-Oxide businesses.
- Examine the pro forma financial information to understand the impact of the acquisition on the company's consolidated financial position.
- Confirm the terms of the $660 million New Term Loan Facility and $250 million Senior Notes used to fund the deal.